ImmunityBio, Inc. (IBRX) Down 5.2% — Time to Execute the Exit Plan?
ImmunityBio, Inc. (IBRX) is retreating on Tuesday, last changing hands at $9.85 on the NASDAQ — a $0.53 decline from the prior close of $10.38. The pullback leaves the stock roughly 20.8% below its 52-week high of $12.43, reached on February 25, 2026. It still trades more than five times above the bottom of its 52-week range of $1.95. That spread shows how dramatically the name has rerated over the past year, and how much room remains for sharp swings in either direction.
Volume stands at approximately 10.63 million shares so far, against a 90-day average of roughly 11.12 million. Turnover is running close to normal levels, and the selling has not yet spilled into heavier-than-usual activity this session.
Why ImmunityBio, Inc. Price is Moving Lower
The most plausible driver is a broad retreat across biotech. The SPDR S&P Biotech ETF (XBI) was down 3.57% at 10:24 a.m. ET, and the iShares Biotechnology ETF (IBB) was off 2.38% at 10:12 a.m. ET. Higher-beta names in the group are absorbing the worst of it. Moderna, Inc. (MRNA) fell 6.50% and Natera, Inc. (NTRA) dropped 5.56%, both moves in line with or deeper than IBRX's decline. When speculative biotech names fall in tandem with the sector benchmarks, the selling reflects sector-wide risk appetite more than anything specific to one company.
The sector weakness landed on a stock primed for profit-taking. IBRX gained 22% last week, including an 11% surge on Friday, after retail investors speculated that a new appointment to the presidential Cancer Panel could help Anktiva gain broader access. That rally was driven by speculation rather than a confirmed commercial or regulatory development, which left the gains exposed once the broader tape turned. Separately, officer and director Barry Simon filed notice on October 5 of a proposed sale of 560,000 shares valued at about $7.66 million. Against a $10.90 billion market cap, that filing is background noise rather than a driver. It may still add modest overhang for traders already inclined to lock in last week's gains.
The fundamental backdrop gives buyers mixed signals. ImmunityBio's Q2 results, released on August 4, showed revenue of $51.24 million against a $49.70 million estimate, a beat that represented 94% year-over-year growth as Anktiva sales scaled. The bottom line went the other way. GAAP EPS came in at -$0.22 versus the -$0.08 consensus, and the net loss widened to $230.4 million from $92.6 million a year earlier, largely reflecting non-cash fair-value changes. The next major catalyst is on January 6, 2027 — the FDA's decision on Anktiva plus BCG for papillary-only, BCG-unresponsive bladder cancer. Until then, the stock is likely to trade on sector sentiment and speculation.
What is the ImmunityBio, Inc. Rating - Should I Sell?
Weiss Ratings assigns IBRX a D- rating. The rating was upgraded on 1/15/2026. Current recommendation is Sell. The January upgrade nudged the rating within Sell territory but did not lift it out, and that leaves a clear message. Shareholders have been rewarded for taking on risk, but the underlying business has not yet reached the profitability or stability that would support a Hold.
The firmest part of the profile is the Good rating on the Total Return Index. A stock that has climbed from a 52-week low of $1.95 to nearly $10 has delivered extraordinary gains to anyone who held through the past year, and that record holds even after today's decline. The Fair rating on the Solvency Index suggests the balance sheet can carry the company through its current commercial ramp without immediate distress. It is not rated higher because a business losing hundreds of millions of dollars per quarter remains dependent on its capital position to fund operations.
Where the picture deteriorates is in the operating metrics. The Weak rating on the Growth Index can look surprising next to 93.91% revenue growth and a 14.7% sequential revenue gain from the first quarter to the second. Top-line momentum alone does not carry the rating, however, when EPS sits at -$0.97 and the latest quarter's loss more than doubled year over year. The Very Weak Efficiency Index is the starkest marker. A -598.55% profit margin means Anktiva's sales, while growing quickly, remain a small fraction of what the company spends to develop and commercialize its pipeline. The forward P/E of -10.60 confirms that losses are expected to persist. The Weak Volatility Index needs little explanation for a stock that swung 11% higher on Friday on retail speculation and is now falling more than 5% in a sector-wide biotech selloff.
Within the Health Care sector, ImmunityBio sits alongside Moderna, Inc. (MRNA, D-), Natera, Inc. (NTRA, D-), and Revolution Medicines, Inc. (RVMD, D-). It ranks slightly below Zoetis Inc. (ZTS, D), whose more established earnings base still falls short of a Hold. The concentration of Sell ratings among these names reflects how much speculative risk is priced into the group.
About ImmunityBio, Inc.
ImmunityBio, Inc. (IBRX) is a Health Care company based in San Diego, California. It develops and commercializes next-generation immunotherapies designed to activate the patient's own immune system against cancer and infectious diseases. Its platforms span cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. They have produced first-in-human therapeutic agents intended for clinical study in both liquid and solid tumors.
The company's commercial anchor is Anktiva, an FDA-approved immunotherapy used in combination with bacillus Calmette-Guérin (BCG) to treat adult patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. Expanding Anktiva's label is central to the growth case, including the pending application in papillary-only disease. ImmunityBio also holds rights to 3M-052, a synthetic TLR7/8 agonist, along with related formulations and technology licensed from 3M Innovative Properties Company. It holds a separate license agreement with Access to Advanced Health Institute.
The company's competitive position rests on having an approved, revenue-generating product in a bladder cancer population with limited options, backed by a broader immunotherapy platform that could extend Anktiva into additional indications. Collaborations with the National Cancer Institute, Serum Institute of India Private Limited, and BeOne Medicines Ltd. widen its clinical and manufacturing reach. Those advantages still depend on regulatory outcomes and on whether commercial uptake can scale fast enough to narrow the company's sizable operating losses.
Investor Outlook
ImmunityBio, Inc. (IBRX) carries a Weiss Rating of D- (Sell). Today's pullback shows how quickly speculative gains can unwind when biotech sentiment turns. Investors should watch the FDA's January 6, 2027, decision on Anktiva in papillary-only bladder cancer, and whether upcoming quarterly results show revenue growth finally narrowing a loss that reached $230.4 million last quarter. See full rankings of all D- rated Health Care stocks inside the Weiss Stock Screener.
--